1. A class action lawsuit has been filed against LifeMD, Inc. (LFMD). 2. Claims allege violations of securities laws and misleading market statements. 3. Investors from May to August 2025 may join the class action. 4. False statements regarding fiscal guidance led to investor damages. 5. The firm has not yet certified the class for legal representation.
The lawsuit implies significant investor distrust due to alleged deception, impacting share value. Historically, companies facing similar lawsuits often experience drops in stock prices, e.g., Theranos.
The news indicates serious legal challenges that could impact LFMD’s operations and investor sentiment significantly.
Legal proceedings can rapidly affect stock performance, especially with active litigation. Markets often react to such negative news almost immediately, as seen in recent market reactions.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD" or "the Company") (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 7, 2025 and August 5, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before October 27, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. LifeMD misled investors about the strength of its competitive position. The Company raised its guidance for fiscal year 2025 performance without the basis to do so, ignoring factors such as customer acquisition costs for weight loss drugs. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about LifeMD, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250827096889/en/
The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com